Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 190

Similar articles for PubMed (Select 21203579)

1.

HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.

Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A.

PLoS Biol. 2010 Dec 21;8(12):e1000563. doi: 10.1371/journal.pbio.1000563.

2.

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.

Exp Cell Res. 2005 Apr 1;304(2):604-19. Epub 2005 Jan 21.

PMID:
15748904
4.

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.

5.

Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.

Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, Brockhoff G.

Breast Cancer Res. 2009;11(4):R50. doi: 10.1186/bcr2339. Epub 2009 Jul 22.

6.

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.

Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.

Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3.

7.
8.

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.

Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B.

PLoS One. 2008 Aug 6;3(8):e2881. doi: 10.1371/journal.pone.0002881.

9.

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.

Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28.

10.
11.

EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.

Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.

Breast Cancer Res Treat. 2010 Aug;122(3):685-97. doi: 10.1007/s10549-009-0592-x. Epub 2009 Oct 27.

PMID:
19859802
12.

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A.

Oncotarget. 2013 Oct;4(10):1592-605.

13.

HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.

Huang X, Wang S, Lee CK, Yang X, Liu B.

Cancer Lett. 2011 Aug 1;307(1):72-9. doi: 10.1016/j.canlet.2011.03.019. Epub 2011 Apr 16.

PMID:
21497990
14.

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].

Dieras V, Vincent-Salomon A, Degeorges A, Beuzeboc P, Mignot L, de Cremoux P.

Bull Cancer. 2007 Mar;94(3):259-66. Review. French.

PMID:
17371768
16.

Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.

Gu L, Waliany S, Kane SE.

PLoS One. 2009 Jul 13;4(7):e6220. doi: 10.1371/journal.pone.0006220.

17.

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.

Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX.

Cancer Cell. 2009 May 5;15(5):429-40. doi: 10.1016/j.ccr.2009.03.020. Erratum in: Cancer Cell. 2011 Dec 13;20(6):818.

18.

Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer.

Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J.

Mol Cancer Ther. 2004 Dec;3(12):1585-92.

19.

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.

Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J.

Oncogene. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626. Epub 2011 Jan 31.

20.

Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.

Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D.

Cancer Res. 2002 Oct 15;62(20):5703-10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk